

PRESSRELEASE

OptiCell Solutions AB announce the addition of Mr. Henrik Fahlander as the Technically Responsible Person. Huddinge, Sweden 09-JAN-2025

OptiCell Solutions AB is delighted to announce the addition of Mr. Henrik Fahlander to our team as the Technically Responsible Person. Henrik brings invaluable experience and expertise that will be pivotal as we advance in the field of apheresis and cell collection for cell and gene therapy.

Henrik Fahlander is a registered nurse with 30 years of clinical experience, the last 17 years from the Apheresis Unit at Karolinska University Hospital as a technically responsible person. Driven by a commitment to improving customer outcomes and promoting innovative medical technology in R&D, Henrik leverages his extensive experience to deliver impactful results.

At OptiCell Solutions, Henrik's goal is to optimize apheresis services to deliver the highest quality target cells for research and clinical applications. By optimizing parameters and adapting apheresis procedures to meet specific customer requirements in collaboration with researchers, Henrik can evaluate results and continuously improve apheresis methods.

"We are thrilled to have Henrik join our team," said Jarmo Henriksson, CEO of OptiCell Solutions AB. "His wealth of knowledge and commitment to advancing apheresis will be instrumental in driving OptiCell Solutions' mission to provide high-quality, patient-centered services for cell and gene therapy."

Mr. Henrik Fahlander's expertise in both clinical and research environments strengthen our capabilities to deliver cutting-edge solutions in cellular therapy. His commitment to quality aligns perfectly with our mission to enhance patient care and safety.

--- END PRESSRELEASE---

For more information, please contact

General Manager, Jarmo Henriksson, +46 (0) 73 699 48 37, jarmo.henriksson@opticellsolutions.com
Chairman of the board, Peter Rybäck, +46 (0) 73 849 07 96, peter.ryback@opticellsolutions.com

About OptiCell Solutions

Founded in 2024, OptiCell Solutions AB specializing in the field of apheresis and cell collection for cell and gene therapy (CAGT). By using our advanced apheresis technology, we can collect large quantities of specific donor cells, significantly advancing CAGT applications within in the biotech and healthcare sector. Furthermore, our extensive experience and know-how in apheresis enable us to offer specialized therapeutic apheresis services to the healthcare sector.

Located near the Karolinska University Hospital in Huddinge we aim to bridge the gap in resources by offering innovative solutions that enhance the availability of essential cells for cutting-edge research and life-saving therapies. With our deep expertise in apheresis technology and a strong commitment to ethical research practices, we are dedicated to improving patient outcomes and supporting the development of next-generation therapies for cancer care, autoimmune diseases, and other severe medical conditions.

At OptiCell Solutions, we strive to be at the forefront of medical innovation, providing the tools and services necessary to accelerate the transition to more effective and patient-centred care. For more information visit our website, www.opticellsolutions.com and follow us at [LinkedIn](#).